8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control

8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in Canadian clinical practice, affecting approximately 1% to 2% of the population and > 10% of individuals aged 80 and older. It is characterized by chaotic, disorganized atrial electrical activation (350 to 600 depolarizations/min) that leads to an irregular, typically rapid ventricular response.

Management of AF rests on three interconnected clinical pillars: (1) Stroke prevention through evidence-based anticoagulation, (2) Ventricular rate control to preserve hemodynamics and prevent tachycardia-induced cardiomyopathy, and (3) Rhythm control (antiarrhythmic drugs, cardioversion, catheter ablation) in selected symptomatic patients.

---

Pathophysiology and Clinical Consequences of Atrial Fibrillation

• Loss of Atrial Systole ('Atrial Kick'): In a healthy heart, active atrial contraction contributes 20% to 30% of left ventricular end-diastolic filling. Loss of this synchronized kick in AF precipitates an immediate decline in cardiac output, frequently triggering acute pulmonary congestion or fatigue in patients with baseline diastolic dysfunction or heart failure.
• Rapid Ventricular Response (RVR): Ventricular rates often range between 110 and 180 bpm at rest. Prolonged uncontrolled tachycardia impairs myocardial perfusion, increases oxygen demand, and causes tachycardia-induced cardiomyopathy—a reversible form of systolic heart failure.
• Thromboembolic Stroke: Ineffective, fibrillating atria create regional blood stasis, predominantly within the trabeculated left atrial appendage (LAA). Thrombi formed in the LAA can embolize through the carotid circulation, resulting in severe ischemic stroke. AF-related strokes are notoriously larger, more disabling, and associated with double the mortality of non-AF strokes.

---

Stroke Prevention: The CCS-CHADS-65 Algorithm

Unlike American and European guidelines that rely on the complex CHA2DS2-VASc score, the Canadian Cardiovascular Society (CCS) developed the streamlined CCS-CHADS-65 algorithm. This algorithm recognizes that age >= 65 is the single most powerful continuous risk factor for stroke, rendering additional risk scoring above age 65 redundant.

                    CCS-CHADS-65 DECISION ALGORITHM
 ┌─────────────────────────────────────────────────────────────────────────────┐
 │ Patient with Documented Atrial Fibrillation or Atrial Flutter               │
 └──────────────────────────────────────┬──────────────────────────────────────┘
                                        ▼
          Mechanical Heart Valve or Moderate-to-Severe Mitral Stenosis?
                    ┌───────────────────┴───────────────────┐
                   YES                                     NO
                    │                                       ▼
                    ▼                         Age >= 65 OR Prior Stroke / TIA?
        WARFARIN MANDATORY (Target 2.5-3.5)                 │
        (DOACs are CONTRAINDICATED)           ┌─────────────┴─────────────┐
                                             YES                          NO
                                              │                           ▼
                                              │             Presence of CHADS Risk Factors?
                                              │             - Congestive Heart Failure
                                              │             - Hypertension
                                              │             - Diabetes Mellitus
                                              │                           │
                                              │               ┌───────────┴───────────┐
                                              │              YES                      NO
                                              │               │                       ▼
                                              ▼               ▼         Arterial Vascular Disease?*
                                      ORAL ANTICOAGULATION                    │
                                      (DOAC Preferred over Warfarin)  ┌───────┴───────┐
                                                                     YES              NO
                                                                      │               ▼
                                                                      ▼          NO ANTITHROMBOTIC
                                                                  ASA 81 mg        THERAPY
                                                                    daily

*Arterial vascular disease includes prior myocardial infarction, peripheral arterial disease, or complex aortic plaque.

Detailed Steps of the CCS Algorithm:

1. Valvular AF Screen: If the patient has a mechanical prosthetic heart valve or moderate-to-severe rheumatic mitral stenosis, the patient has 'valvular AF' and requires Warfarin (INR target 2.5 to 3.5 for mechanical mitral, 2.0 to 3.0 for mechanical aortic). DOACs are strictly contraindicated in mechanical heart valves (RE-ALIGN trial).
2. Age & Stroke History: If non-valvular, does the patient meet Age >= 65 OR have a history of prior Stroke, TIA, or systemic embolism? If YES --> Oral Anticoagulation (OAC) is recommended regardless of other factors.
3. CHADS Risk Factors: If Age < 65 without prior stroke/TIA, evaluate the remaining CHADS risk factors:
   • C: Congestive Heart Failure (recent decompensation, HFrEF, or HFpEF)
   • H: Hypertension (treated or untreated blood pressure > 140/90 mmHg)
   • D: Diabetes mellitus (type 1 or type 2)
   • If the patient has >= 1 of these risk factors --> Oral Anticoagulation (OAC) is recommended.
4. No CHADS Risk Factors: If Age < 65 and none of the CHADS risk factors are present:
   • Check for Arterial Vascular Disease (coronary artery disease, prior MI, coronary stent, peripheral arterial disease):
     • If vascular disease is present --> ASA 81 mg once daily.
     • If NO vascular disease is present --> No antithrombotic therapy.

---

Rate Control vs. Rhythm Control Strategy

The fundamental clinical decision in managing AF symptoms is whether to pursue rate control or rhythm control:

• Landmark Clinical Evidence: The landmark AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) and RACE trials demonstrated that a routine rhythm-control strategy using antiarrhythmic drugs does not improve survival or reduce stroke risk compared to a rate-control strategy. Antiarrhythmic medications were associated with more adverse drug reactions, proarrhythmic events, and hospitalizations.
• Rate Control as Default: Rate control is the preferred initial strategy for the majority of elderly, sedentary, or minimally symptomatic patients.
• Indications for Rhythm Control:
  • Persistent, debilitating symptoms (fatigue, palpitations, dyspnea) despite adequate rate control.
  • Inability to achieve target ventricular rate control with safe doses of AV nodal blockers.
  • Heart failure clearly precipitated or worsened by AF (tachycardia-induced cardiomyopathy).
  • Younger patients wishing to avoid lifelong rate-controlling medications.
  • Newly diagnosed AF within 1 year, where early rhythm control (antiarrhythmics or catheter ablation) has been shown to reduce cardiovascular death and stroke (EAST-AFNET 4 trial).

---

Ventricular Rate Control Pharmacotherapy

Rate control slows conduction velocity and prolongs the refractory period of the atrioventricular (AV) node, protecting the ventricles from rapid atrial impulses.

Target Heart Rate: Lenient vs. Strict Control

• Lenient Rate Control: Resting heart rate < 110 bpm. In the RACE II trial, lenient rate control was proven to be non-inferior to strict control regarding cardiovascular mortality, heart failure hospitalizations, and stroke, with significantly fewer clinic visits and drug dose titrations.
• Strict Rate Control: Resting heart rate < 80 bpm and exercise heart rate < 110 bpm. Indicated if the patient remains symptomatic under lenient control, or in patients with HFrEF or suspected tachycardiomyopathy.

Rate Control Agents: Clinical Comparison

---

Rhythm Control Pharmacotherapy: Antiarrhythmic Drugs (AADs)

Antiarrhythmic drugs are classified using the Vaughan Williams classification system. In atrial fibrillation, rhythm control relies primarily on Class Ic and Class III agents.

1. Class Ic Agents: Flecainide & Propafenone

• Mechanism: Potent sodium channel blockers that significantly slow phase 0 cardiac depolarization and conduction velocity without altering action potential duration.
• Clinical Indications: Maintenance of sinus rhythm or chemical cardioversion in patients with structurally normal hearts (absence of ischemic heart disease, prior MI, left ventricular hypertrophy, or heart failure).
• The 'Pill-in-the-Pocket' Strategy: In selected outpatients with infrequent, symptomatic episodes of paroxysmal AF, a self-administered single oral dose of flecainide (200 to 300 mg) or propafenone (450 to 600 mg) can terminate the arrhythmia at home, avoiding emergency department visits.

2. Class III Agents: Amiodarone, Sotalol & Dronedarone

Class III antiarrhythmics block cardiac potassium repolarizing channels, prolonging the action potential duration and effective refractory period.

A. Amiodarone (Cordarone)

• Efficacy: The most effective antiarrhythmic drug for maintaining sinus rhythm and the only agent proven safe in patients with severe structural heart disease, severe left ventricular hypertrophy, and HFrEF.
• Pharmacokinetics: Extremely lipophilic with a massive apparent volume of distribution (Vd > 60 L/kg) and a prolonged elimination half-life of 40 to 60 days. Contains two iodine atoms, representing 37% iodine by molecular weight.
• Organ Toxicities & Monitoring Protocol:
  • Pulmonary Toxicity: Pulmonary fibrosis or hypersensitivity pneumonitis occurs in up to 5% of patients and can be fatal. Baseline and annual chest X-ray; pulmonary function tests (DLCO) if dyspnea or cough occurs.
  • Thyroid Dysfunction: Baseline and every 6-month thyroid stimulating hormone (TSH) and free T4. Causes hypothyroidism (blocks peripheral conversion of T4 to T3) or hyperthyroidism (iodine-induced Jod-Basedow effect or destructive thyroiditis).
  • Ocular Deposits: Corneal microdeposits occur in > 90% of patients (harmless, causes halos around lights). However, optic neuropathy or optic neuritis causes progressive visual loss and requires immediate drug cessation.
  • Hepatotoxicity: Serum aminotransferases (AST/ALT) rise in 15% to 30%. Check baseline and every 6-month LFTs; discontinue if transaminases exceed 3 times upper limit of normal.
  • Dermatologic: Photosensitivity (counsel on sunscreen and sun avoidance); prolonged use causes irreversible slate-gray or blue skin pigmentation.
  • Cardiac: Severe bradycardia, AV block, and QT prolongation. Note: Despite marked QTc prolongation, amiodarone causes uniform prolongation of myocardial repolarization and carries a very low incidence (< 1%) of Torsades de Pointes.
• Drug-Drug Interactions: Potent inhibitor of CYP3A4, CYP2C9, CYP2D6, and P-glycoprotein. Empirically reduce the maintenance dose of Digoxin by 50% and Warfarin by 30% to 50% when initiating amiodarone.

B. Sotalol (Sotacor)

• Combines non-selective beta-blockade with Class III potassium channel blockade.
• High Risk of Torsades de Pointes: Significantly prolongs QT interval; risk of proarrhythmia increases with higher doses, hypokalemia, hypomagnesemia, female sex, and renal impairment.
• Safety Mandate: Contraindicated if baseline QTc > 450 ms or creatinine clearance < 30 mL/min. Inpatient continuous ECG telemetry monitoring for at least 3 days (5 to 6 doses) is standard during therapy initiation.

C. Dronedarone (Multaq)

• Non-iodinated amiodarone derivative designed to minimize pulmonary and thyroid toxicity.
• Critical Contraindications: Contraindicated in patients with permanent AF (PALLAS trial) and in patients with NYHA Class III to IV or recently decompensated HFrEF (ANDROMEDA trial), where it significantly increased cardiovascular death.

---

Cardioversion Rules and Anticoagulation Mandates

Restoration of sinus rhythm via synchronized direct-current electrical cardioversion (DCCV) or chemical cardioversion carries an inherent risk of dislodging a pre-existing atrial thrombus:

                  CARDIOVERSION ANTICOAGULATION PROTOCOL
 ┌─────────────────────────────────────────────────────────────────────────────┐
 │ Patient with AF Scheduled for Cardioversion (Electrical or Chemical)       │
 └──────────────────────────────────────┬──────────────────────────────────────┘
                                        ▼
                            AF Duration >= 48 Hours?
                    ┌───────────────────┴───────────────────┐
                   YES (or Unknown Duration)               NO (< 48 Hours)
                    │                                       │
        ┌───────────┴───────────┐                           ▼
        ▼                       ▼                 Cardiovert Promptly;
    OPTION 1:               OPTION 2:             Administer Anticoagulant
  Therapeutic OAC         TEE Guided:             at presentation;
  for >= 3 WEEKS          Perform TEE;            Continue Anticoagulation
  PRIOR to                If NO LAA thrombus,     for >= 4 WEEKS
  Cardioversion           Cardiovert with         post-cardioversion
        │                 Heparin/DOAC                    │
        └───────────┬───────────┘                         │
                    ▼                                     ▼
        Cardioversion Performed               Cardioversion Performed
                    │                                     │
                    ▼                                     ▼
  CONTINUE THERAPEUTIC ANTICOAGULATION  CONTINUE THERAPEUTIC ANTICOAGULATION
  FOR AT LEAST 4 WEEKS POST-PROCEDURE   FOR AT LEAST 4 WEEKS POST-PROCEDURE
  (Atrial stunning persists for weeks)  (Lifelong if CCS-CHADS-65 >= 1)

1. AF Duration >= 48 Hours (or Unknown Duration):
   • Option 1 (Standard): Therapeutic oral anticoagulation (DOAC or warfarin with INR 2.0 to 3.0) for a minimum of 3 consecutive weeks prior to cardioversion, followed by therapeutic anticoagulation for at least 4 weeks post-cardioversion.
   • Option 2 (TEE-Guided): Perform a transesophageal echocardiogram (TEE) to directly visualize the left atrial appendage. If no thrombus is detected, cardioversion may be performed immediately after administering therapeutic anticoagulation (e.g., LMWH, IV heparin, or a DOAC dose). Therapeutic anticoagulation must still be continued for at least 4 weeks post-cardioversion.
2. Why 4 Weeks Post-Cardioversion?: Even after sinus rhythm is successfully restored, the mechanical pumping function of the atria remains impaired for days to weeks—a phenomenon known as atrial stunning. Thrombi can form in stunned atria even in sinus rhythm; therefore, 4 weeks of post-procedure anticoagulation is non-negotiable.
3. Long-Term Anticoagulation: After the 4-week post-cardioversion window, the decision to continue lifelong anticoagulation is based solely on the patient's underlying CCS-CHADS-65 stroke risk profile, NOT on maintenance of sinus rhythm.
4. Hemodynamically Unstable AF: In patients presenting with acute pulmonary edema, cardiogenic shock, or severe myocardial ischemia, immediate synchronized electrical cardioversion is mandatory. Therapeutic anticoagulation (IV heparin bolus or LMWH) should be administered immediately prior to shock, followed by 4 weeks of post-cardioversion anticoagulation.